Apomorphine

Generic Name
Apomorphine
Brand Names
Apokyn
Drug Type
Small Molecule
Chemical Formula
C17H17NO2
CAS Number
58-00-4
Unique Ingredient Identifier
N21FAR7B4S
Background

Apomorphine is a non-ergoline dopamine D2 agonist indicated to treat hypomobility associated with Parkinson's. It was first synthesized in 1845 and first used in Parkinson's disease in 1884. Apomorphine has also been investigated as an emetic, a sedative, a treatment for alcoholism, and a treatment of other movement disorders.

Apomorphine was granted FDA approval on 20 April 2004.

Indication

Apomorphine is indicated to treat acute, intermittent treatment of hypomobility, off episodes associated with advanced Parkinson's disease.

Associated Conditions
Mobility decreased
Associated Therapies
-
Clinical Trials
Related News

Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)

First Posted Date
2013-01-17
Last Posted Date
2023-08-14
Lead Sponsor
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
Target Recruit Count
127
Registration Number
NCT01770145
Locations
🇺🇸

Henry Ford West Bloomfield Hospital, Bloomfield Hills, Michigan, United States

🇺🇸

University of Texas Health Science Center, Houston, Department of Neurology, Houston, Texas, United States

🇺🇸

Center for Neurological Care and Research, San Antonio, Texas, United States

and more 9 locations

Apomorphine Effects on Experimental Pain

Early Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Apomorphine
First Posted Date
2012-12-07
Last Posted Date
2016-09-16
Lead Sponsor
Rambam Health Care Campus
Target Recruit Count
105
Registration Number
NCT01744964
Locations
🇮🇱

Rambam Health Care Campus, Haifa, Israel

Efficacy Study of NH001 in Vegetative State & Minimally Conscious State Following a Traumatic Brain Injury

Phase 2
Suspended
Conditions
Brain Injury
Interventions
Drug: Placebo
Drug: Apomorphine
First Posted Date
2008-09-29
Last Posted Date
2017-03-31
Lead Sponsor
NeuroHealing Pharmaceuticals Inc.
Target Recruit Count
76
Registration Number
NCT00761228
Locations
🇺🇸

Spaulding Rehabilitation Hospital, Boston, Massachusetts, United States

Comparison of Continuous and Pulsatile Apomorphine in Parkinson's Disease

Phase 2
Withdrawn
Conditions
Parkinson's Disease
Interventions
Drug: Apomorphine
First Posted Date
2008-09-25
Last Posted Date
2018-11-02
Lead Sponsor
Oregon Health and Science University
Registration Number
NCT00758368
Locations
🇺🇸

Oregon Health and Science University, Portland, Oregon, United States

Apomorphine Effect on Nociceptive Perception in Parkinson's: a Clinical and Imaging Study

Not Applicable
Completed
Conditions
Parkinson's Disease
Interventions
Drug: placebo
Drug: apomorphine
First Posted Date
2007-09-05
Last Posted Date
2008-04-11
Lead Sponsor
University Hospital, Toulouse
Target Recruit Count
16
Registration Number
NCT00524914
Locations
🇫🇷

Service de Neurologie, Toulouse, France

Low Dose Apomorphine and Parkinsonism

Phase 2
Withdrawn
Conditions
Parkinson's Disease
First Posted Date
2007-05-11
Last Posted Date
2018-11-29
Lead Sponsor
Oregon Health and Science University
Registration Number
NCT00472355
Locations
🇺🇸

Department of Neurology, Oregon Health and Science University, Mail Code OP32, 3181 SW Sam Jackson Park Road, Portland, Oregon, United States

Relationship Between D2 Receptors SPECT and the Apomorphine Test in Patients With OH Dependence (ALC-DRD2-APO)

Phase 2
Conditions
Alcoholism
First Posted Date
2007-02-19
Last Posted Date
2009-04-29
Lead Sponsor
Hospital Universitari Vall d'Hebron Research Institute
Target Recruit Count
50
Registration Number
NCT00437177
Locations
🇪🇸

Psychiatry Service, Hospital Universitari Vall d'Hebron, Barcelona, Catalonia, Spain

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy